Skip to main content
S&P 5007,541.40-0.51%DOW51,983.98+0.41%NASDAQ25,164.36-1.07%BTC$77,142.00-1.60%ETH$2,258.53-1.35%GOLD$3,958.40-0.28%OIL$96.61+0.16%
Smart Investors Daily
SID Premium
AV

NASDAQ · AVR

Anteris Technologies Global Corp.

Healthcare · Medical - Devices

$5.78

Down-$0.53 (-8.40%)

Updated Nov 3, 2026, 4:56 AM

SID Score

4.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
172.44M
P/E ratio
-1.47
Dividend yield
0.00%
52-week range
$3.30 – $11.06
Volume
4.02M
Avg. volume
248.1K

Price performance · AVR

AVR price history

1M range · 0 trading sessions · Daily adjusted prices

AVR does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest AVR news

The latest Smart Investors Daily articles mentioning AVR.

Stock researchCompany · Overview

AVR research

Overview

Company profile and research snapshot.

Company profile

Anteris Technologies Global Corp is a structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Its product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with the world's interventional cardiologists and cardiac surgeons to treat aortic stenosis a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. Company operates in USA, Germany, Australia, Switzerland, and Sweden. Majority of revenue is from USA.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$9.00
Implied upside
—
Analysts
—
AVR recent ratings
DateFirmRatingTarget
Oct 14, 2026Cantor FitzgeraldOverweight—
Oct 7, 2026BarclaysEqual-Weight—
Aug 14, 2026Cantor FitzgeraldOverweight—
May 15, 2026BarclaysOverweight—
Mar 27, 2026Cantor FitzgeraldOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

Anteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026

MINNEAPOLIS and BRISBANE, Australia, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) today announced that Azeem Latib, MD, will present the first 30-day clinical and hemodynamic outcomes for its medium-size DurAVR® Transcatheter Heart Valve (THV) at TCT® 2026 – The 38th Annual Transcatheter Cardiovascular Therapeutics Conference, taking place in San Diego, California, October 31-November 3, 2026. The presentation will repor

Yahoo · Oct 20, 2026

Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance

MINNEAPOLIS and BRISBANE, Australia, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced today that it has received full regulatory clearance from the German Federal Institute for Drugs and Medical Devices (BfArM) for the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial for patients with severe calcific aortic stenosis (the “PARADIGM Trial”). This clearance enables Anteris to initiate patient recruitment a

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By